Beckett N, Peters R, Tuomilehto J, et al. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial BMJ. 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
HYVET 1-year extension: Immediate and late benefits with indapamide SR ± perindopril in the treatment of hypertensive patients.
HYVET 1-year extensionHYVET 1-year extension11 Study protocolStudy protocol
3.1 years on active treatment
1 year on active treatment
n= 3845 patients n= 1712 patients
Placebo
Placebo
Indapamide SR± perindopril
Indapamide SR± perindopril
Indapamide SR± perindopril
2.1 years 1-year extension2.1 years
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
vs.
HYVET HYVET 11 ResultsResults
n= 3845 patients
Placebo
Placebo
Indapamide SR± perindopril
2.1 yearsStroke hazard ratio: -39% P =0.05 in favor of the indapamide SR ± perindopril group.
Heart failurehazard ratio: -64% P<0.001 in favor of the indapamide SR ± perindopril group.
All-cause mortality hazard ratio: -21% P=0.02 in favor of the indapamide SR ± perindopril group.
1. Beckett NS, Peters R, Fletcher AE, et al. N Engl J Med. 2008;358:1887-1898.
Cardiovascular events hazard ratio: -34% P<0.001 in favor of the indapamide SR ± perindopril group.
Cardiovascular mortality hazard ratio: -23% P=0.06 in favor of the indapamide SR ± perindopril group.
vs.
HYVET 1-year extensionHYVET 1-year extension11 Study protocolStudy protocol
3.1 years on active treatment
1 year on active treatment
n= 3845 patients n= 1712 patients
Placebo
Placebo
Indapamide SR± perindopril
Indapamide SR± perindopril
Indapamide SR± perindopril
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
2.1 years 1-year extension
vs.
No significant difference between the two arms in:- Stroke P=0.28- Heart failure P=0.28- Cardiovascular events P=0.55
HYVET 1-year extensionHYVET 1-year extension11 ResultsResults
• Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events
• These benefits appeared within 1 year of starting treatment
• Indapamide SR ± perindopril provides patients with immediate protection against stroke, heart failure, and cardiovascular events
• These benefits appeared within 1 year of starting treatment
n= 3845 patients n= 1712 patients
Placebo
Placebo
Indapamide SR± perindopril
Indapamide SR± perindopril
Indapamide SR± perindopril
2.1 years 1-year extension
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
vs.
• Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term.
• Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term.
Total mortality hazard ratio: -52% P =0.02 in favor of the group treated for 3.1 years.
Cardiovascular mortality hazard ratio: -81% P =0.03 in favor of the group treated for3.1 years.n= 3845 patients n= 1712 patients
Placebo
Placebo
Indapamide SR± perindopril
Indapamide SR± perindopril
Indapamide SR± perindopril
2.1 years 1-year extension
HYVET 1-year extensionHYVET 1-year extension11 ResultsResults
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
vs.
• Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term.
• Indapamide SR ± perindopril provides cumulative time-dependent life-saving benefits, increased over the long term.
HYVET 1-year extensionHYVET 1-year extension11 ResultsResults
1. Beckett N, Peters R, Tuomilehto J, et al. BMJ 2012;344:d7541 doi: 10.1136/bmj.d7541 (Published 4 January 2012)
Total mortality Cardiovascular mortality
P=0.02
P=0.03
-52%
-81%